Form 8-K · Current Report · Filed 2025-05-13
AbbVie Expands Board and Announces Leadership Changes
AbbVie Inc. expanded its Board of Directors by appointing Thomas J. Falk as a Class III director and announced changes to its leadership, including the election of Robert A. Michael as Chairman, effective July 1, 2025. The company also reported on the outcomes of its 2025 Annual Meeting of Stockholders, including the election of Class I directors, ratification of Ernst & Young LLP as independent auditors, and stockholder votes on executive compensation and governance proposals.
- Filer
- AbbVie Inc. ABBV · NYSE
- Filed
- Accession
- 0001104659-25-047402
- CIK
- 0001551152
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Submission of Matters to a Vote of Security Holders
Market reaction
Close before filing
$190.07
Next session
-6.6%
Since filing
+32.0%
Latest close
$250.94
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ABBV reporting the same item, with the next session's move:
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Never miss another ABBV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.